Amgen (NASDAQ:AMGN) recalled Friday certain lots of its treatment of anemia-related-to-HIV therapy, chronic renal failure and chemotherapy due to the possibility that the drug may contain barely visible thin glass flakes.
Vials of Epogen and Procrit will be recalled from specialty distributors, wholesalers, pharmacies and healthcare providers.
The glass, or lamellae, results from the interaction of the formula with glass vials over the shelf life of the product.
In a statement, the company said the voluntary recall is just precautionary, with no recorded complaints.
Evaluations by the company and Centocor Ortho Biotech Products found a low potential to impact patients who have received the affected product.
Possible serious adverse effects via the use of a sterile injectable device include embolic, thrombotic and other vascular events. If the drug is taken by the subcutaneous route, effects could include foreign body granuloma, local injection site reactions and increased immunogenicity.
Consumers are advised to contact their physician or healthcare provider if they experience any problems that may be related to taking the drug.